Category: 8. Health

The addition of the hormone progesterone to gender-affirming hormone therapy leads to increased breast growth for transgender people following feminizing hormone therapy. This is demonstrated by an Amsterdam UMC-led trial among 90 participants and these results are presented today at the European Professional Association for Transgender Health (EPATH) annual congress in Hamburg.

Our results show that progesterone is safe and effective for transgender people. We’re now able to prescribe it, in a trial setting, for those who have been taking oestradiol for at least year. We hope that our findings lead to better hormone treatments for transgender individuals.”

Koen Dreijerink, endocrinologist at Amsterdam UMC

Gender-affirming hormone therapy helps an individual’s body better align with their gender identity. In the case of feminizing hormone therapy this involves blocking the action of testosterone and the addition of estradiol. Traditionally, any breast growth is then limited, leading many transgender people to ultimately opt for breast augmentation surgery.

Breast growth

Alongside estradiol, progesterone is one of the two key female sex hormones. Progesterone is known in cis women to also cause breast growth. However, progesterone has not been prescribed in transgender people due to a lack of evidence of its effectiveness and safety. In order to gain more information of the effect on breast volume as well as the safety of progesterone, Dreijerink and his colleagues conducted a randomly controlled trail between 2021 and 2024.

“Among our 90 participants we repeatedly used 3D-scanning techniques to measure breast volume and saw up to an increase of 37%. Crucially, we also saw that the study participants were more satisfied with the size, shape and the growth of their breasts,” adds Raya Geels, PhD candidate at Amsterdam UMC and the study’s first author.

The largest increase was seen in the group who also increased their estradiol dosage with some frequent side effects such as short-lasting tiredness, breast and nipple sensitivity and mood swings.

Participants in the study used progesterone for a year. “The reason we’re moving forward with prescribing this in a research setting is to learn about the long-term effects and side-effects, for example we know that progesterone causes drowsiness so we advised our participants to take it prior to sleeping” adds Dreijerink. “It’s important that we keep learning about the effects of gender affirming hormone therapy”.

The addition of benmelstobart (TQB2450) to anlotinib (Fukewei) exhibited advantageous progression-free survival (PFS) outcomes vs sunitinib (Sutent) in the treatment of patients who are Chinese with previously untreated advanced clear cell renal cell carcinoma (ccRCC), according to findings from the phase 3 ETER100 trial (NCT04523272) published in The Lancet Oncology.¹

Efficacy data revealed that at a median follow-up of 22.8 months (IQR, 15.2-29.7) for the interim analysis, 48% of the benmelstobart arm and 21% of the sunitinib arm were still receiving treatment, with the primary reason for discontinuation being disease progression in both arms. Additionally, disease progression per blinded independent review committee (BIRC) or death occurred in 48% vs 55% of the respective arms. The median PFS was 19.0 months (95% CI, 15.3-22.8) vs 9.8 months (95% CI, 8.4-12.4), respectively (HR, 0.53; 95% CI, 0.42-0.67; P <.0001).

In a per-protocol set, the median BIRC-assessed median PFS was 19.0 months (95% CI, 16.5-22.8) vs 11.0 months (95% CI, 8.5-13.6) in the combination and control arms, respectively (HR, 0.55; 95% CI, 0.43-0.70; P < .0001). The between-group difference met the prespecified threshold for significance (P = .0153). Additionally, the Kaplan-Meier estimates for PFS at 12 months were 65% (95% CI, 59%-71%) in the combination arm vs 44% (95% CI, 37%-51%) in the control arm; a post hoc analysis of 24-month PFS showed values of 42% (95% CI, 34%-49%) vs 26% (95% CI, 18%-33%).

Subgroup analyses generally favored the benmelstobart combination vs sunitinib, including patients with intermediate-poor International Metastatic RCC Database Consortium (IMDC) risk as well as those with a PD-L1 combined positive score (CPS) of less than 1. Overall survival (OS) data were not mature as of the interim analysis, and 24% vs 30% of patients in each arm had died as of data cut off, mostly due to disease progression.

“The ETER100 trial showed that benmelstobart plus anlotinib resulted in a significant [PFS] benefit and higher objective response rate [ORR] compared with sunitinib in the first-line treatment of advanced [ccRCC],” Aiping Zhou, MD, a professor from the Department of Medical Oncology at the National Cancer Center/Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, China, wrote in the publication with study coinvestigators. “The safety profile of this combination was manageable without new safety signals. These findings support the use of benmelstobart plus anlotinib as an effective and safe therapeutic option for patients with advanced [ccRCC].”

Patients 18 years to 80 years old who are Chinese with previously untreated histologically confirmed advanced ccRCC in the open-label phase 3 trial were randomly assigned 1:1 to received benmelstobart plus anlotinib (n = 264) or sunitinib (n = 263). Treatment in the combination arm consisted of 1200 mg of benmelstobart on day 1 of 3-week cycles and anlotinib given orally at 12 mg daily for the first 2 weeks of each cycle. Those in the control arm received 50 mg of daily sunitinib for the first 4 weeks of 6-week cycles.

Across the investigational and control arms, the median age was 60 years (IQR, 54-67) vs 59 years (IQR, 54-67), with 64% and 69% of each arm being younger than 65 years. Most patients in either arm were male (77% vs 75%), Han (94% vs 94%), and had an ECOG performance score of 1 (73% vs 74%). Additionally, patients most commonly had an intermediate IMDC prognostic risk (71% vs 72%), lung metastases (63% vs 61%), and a PD-L1 CPS of less than 1 (73% vs 72%).

The primary end point of the trial was BIRC-assessed PFS. Secondary end points included investigator-assessed PFS, OS, and ORR assessed by BIRC and investigators.

Per BIRC assessment, the ORR was 72% (95% CI, 66%-77%) with the benmelstobart combination vs 25% (95% CI, 20%-31%) with sunitinib (P <.0001), with a median duration of response (DOR) of 17.9 months (95% CI, 13.7-29.4) vs 16.3 months (95% CI, 10.7-24.5). Based on investigator evaluation, the ORR was 68% (95% CI, 62%-74%) vs 25% (95% CI, 20%-30%) in each arm (P <.0001); the median DOR was 16.8 months (95%CI, 13.9-26.3) vs 16.6 months (95% CI, 8.3-28.8), respectively.

In the safety population, the median duration of treatment in the combination arm was 20 cycles for benmelstobart and anlotinib (IQR; 12-28 and 12-30) vs 6 cycles (IQR, 2-10) for sunitinib. Additionally, the median time to first dose interruption or reduction was 19 weeks, 20 weeks, and 7 weeks, respectively.

Any-grade treatment-emergent adverse effects (TEAEs) occurred in 99% vs 99% of the investigational and control arms, with 75% vs 75% experiencing grade 3 or higher TEAEs. Furthermore, treatment-related AEs (TRAEs) occurred in 98% of each arm, with grade 3 or higher TRAEs occurring in 67% vs 66% of each arm.Common grade 3 or higher TRAEs were hypertension (34% vs 21%), platelet count decreases (1% vs 23%), neutrophil count decreases (2% vs 16%), white blood cell count decreases (1% vs 11%), and anemia (1% vs 9%).

Deaths due to treatment occurred in 3 patients in the combination arm due to cardiac-respiratory arrest, renal failure, and an unknown cause. Health-related quality of life data, particularly changes FKSI-15 scores compared with baseline, indicated more favorable outcomes with the benmelstobart-based combination vs sunitinib.

Reference

Zhou A, Shen P, Li J, et al.First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26(9):1145-1157. doi:10.1016/S1470-2045(25)00343-2

A pizza shop with 30 delivery people ought to be able to deliver a lot of pizzas – if their cars don’t break down on the way. Likewise, genes that produce a lot of messenger RNA (mRNA) molecules can build a lot of proteins – if these molecules don’t fall apart before the job gets done.

Inside almost every human cell is DNA, a comprehensive instruction manual for building and maintaining the body. Genes in that manual contain the instructions for making proteins. But those instructions must travel from the cell’s nucleus, where the DNA lives, to the outer region of the cell – the cytoplasm – where proteins are actually made.

That’s where mRNA comes in. Like a messenger, it copies the instructions from the DNA in the nucleus and carries them out to the protein-making machinery. More mRNA typically means more protein – unless the mRNA is unstable and breaks down too quickly. 

“Every mRNA has to die in the end,” says Xinshu Xiao, a professor of integrative biology and physiology at UCLA and senior author of a new paper published in Nature Genetics. “It’s produced, it does its job, and then it’s destroyed. But most research has focused on how mRNA is made. Much less attention has been paid towards how fast it’s degraded – and that’s just as important.”

Both the production and stability of mRNA can be affected by mutations in the DNA, which are commonly referred to as genetic variants. These variants can affect how much protein a cell makes, and in turn, influence a person’s risk of disease. But figuring out whether a variant affects how much mRNA is made – or how long it survives – has been a major challenge.

Led by UCLA doctoral student Elaine Huang, Xiao’s team developed a computational tool called RNAtracker, which is freely available. The software allows researchers to pinpoint whether a gene is being regulated through changes in mRNA production or in mRNA stability. In pizza terms: Is the problem that not enough pizzas are being made or that the delivery cars are breaking down? RNAtracker helps scientists trace the breakdown.

The researchers applied RNAtracker to a publicly available dataset of 16 human cell lines, in which newly made mRNAs had been chemically labeled and tracked over time. This allowed them to identify genes whose stability varies due to specific mutations. Many of these genes were involved in immune system function – especially the innate immune system, the body’s first line of defense against infections.

The team also found that several of the genetic variants linked to unstable mRNA had already been associated with autoimmune diseases in large-scale genetic studies.

One insight from this project is that some disease-associated variants may be acting through effects on mRNA stability.”

Xinshu Xiao, professor of integrative biology and physiology, UCLA 

Using additional modeling, the researchers linked expression levels of these stability-regulated genes to diseases including allergic rhinitis, lupus, diabetes mellitus and multiple sclerosis. The findings suggest that mRNA stability – long overlooked – may be a key mechanism behind many immune-related diseases.

“Basic research like ours shifts the paradigm of what people focus on,” said Huang. “For drug developers or researchers working on treatments, you can’t target what you don’t know is important. We are trying to bring attention to genetic variants that affect mRNA stability, which hasn’t gotten the spotlight it deserves.”

The research, which received funding from the National Institutes of Health, used publicly available data generated by ENCODE, an NIH-supported consortium.

“The NIH plays a critical role by supporting large-scale efforts like ENCODE,” said Xiao. “They make it possible for researchers around the world to access massive datasets and make discoveries like ours.”

Additional authors include: Ting Fu, Ling Zhang, Guan’ao Yan, Ryo Yamamoto, Sari Terrazas, Thuy Linh Nguyen, Carlos Gonzalez-Figueroa, Armen Khanbabaei, Jae Hoon Bahn, Rajagopal Varada, Kofi Amoah, Jonatan Hervoso, Michelle Paulsen, Brian Magnuson, Mats Ljungman and Jingyi Jessica Li.

A single dose of the psychedelic drug LSD may ease generalized anxiety disorder for months, a clinical trial has found.

The trial results, published Thursday (Sept. 4) in JAMA, include data from 194 people with moderate to severe anxiety across the U.S. The study compared these participants’ responses to different doses of LSD against a placebo treatment. It found that the drug alleviated symptoms in many patients for at least three months after just one exposure.

Fibrosis of the lungs is often a silent disease until it’s too late. By the time patients are diagnosed, the scarring of their lung tissue is already advanced, and current treatments offer little more than a slowing of the inevitable. But what if we could understand the very first steps of this disease before irreversible damage sets in?

That’s the question Claudia Loebel, Reliance Industries Term Assistant Professor in Bioengineering, and Donia Ahmed, a doctoral student in Loebel’s lab, set out to answer. Their Nature Materials paper, a collaborative study spanning the University of Pennsylvania, the University of Michigan and Drexel University, explores how subtle changes in the mechanical environment of lung tissue might set off the chain reaction that leads to fibrosis.

A fresh approach to an intractable disease

Lung fibrosis is notoriously difficult to diagnose and treat. 

Once it’s diagnosed, patients only have two FDA-approved drugs, and both just slow down the disease. They don’t stop it or reverse it. What’s worse is that we often don’t know what caused it in the first place, so we also don’t have a clear idea of how to prevent it.”

Claudia Loebel, Reliance Industries Term Assistant Professor in Bioengineering

Much of the research to date has focused on the later stages of the disease, when tissue has already stiffened and scarred. Loebel and Ahmed decided to flip the script, examining instead what happens right at the onset. Specifically, they looked at how tissue stiffness alone might influence cell behavior in the lungs, offering a new window into fibrosis as it unfolds.

Lighting up the problem

Using a technique called photochemical cross-linking, the researchers exposed lung tissue to blue light, which triggered the extracellular matrix – the fibrous scaffolding surrounding cells – to stiffen. Unlike traditional UV light, blue light is gentler on living cells, making it ideal for studying live tissue.

With these flashes of blue light, the team was able to localize the stiffening of tissue in both healthy mouse and human lung tissue.

“Think of the extracellular matrix like loose hair in a ponytail,” says Ahmed. “With light-triggered cross-linking, we braid it, stiffening the tissue just enough to mimic the kind of micro-injuries that might trigger fibrosis.”

What makes this approach unique is that the team didn’t use engineered gels or decellularized tissue. Instead, they worked with intact, living tissue samples. That preservation of natural cellular and matrix interactions makes their technique a powerful tool for understanding real-time responses to mechanical changes in the lung.

Cells that sense and get stuck

As the tissue stiffened under the light, Ahmed observed that cells began to stretch out, changing shape. And, it wasn’t just cosmetic. This physical stretching was a sign that the cells were transitioning into a different cell type. 

But then they stalled.

“These cells were caught in a sort of identity crisis,” says Ahmed. “They were stuck between types, unable to perform either role well. And that’s a problem.”

These “transitional” cells have been spotted before in fibrotic tissue samples, both in mice and humans. What hasn’t been understood, until now, is how they get there.

Loebel and Ahmed’s model suggests that changes in tissue stiffness alone can prompt cells to begin transitioning, and when they get stuck, they contribute to the very stiffness that triggered them – setting up a potential feedback loop that accelerates disease.

Imagine a child’s play tunnel: when it’s soft and flexible, it’s easy to crawl through. But once it becomes rigid, movement and communication amongst individuals become difficult. Similarly, in a stiffened extracellular matrix, cells can get trapped, lose their function and change shape. Worse, they may attract other “bad” cells that thrive in rigid environments, compounding the damage.

A mechanical problem with biological consequences

While the biology of fibrosis has long been studied, this project reframes the disease as a problem of mechanics. 

“I love thinking about this from a mechanical engineering perspective,” says Ahmed. “It’s not just about chemical signals. The physical environment matters deeply.”

To measure just how stiff the tissue had become, the team used a nanoindenter, an engineering tool typically reserved for testing materials like plastics or metals. They applied it to biological tissue, providing precise data about how stiffness changes in real time.

“We are uniquely positioned to tackle this problem due to our expertise in both engineering and biology,” says Matthew Lee Tan, co-first author and former postdoctoral fellow at the University of Michigan. “This lets us identify opportunities to apply engineering tools to study disease and uncover new biological insights.”

This interdisciplinary approach, combining tools from engineering, insights from biology and models built on real human tissue, reflects the collaborative spirit of Penn Engineering’s scientific ecosystem.

Where to from here?

The team’s leading hypothesis is that these early-responding cells, once stuck in a transitional state, lay the groundwork for fibrosis to progress. They not only lose their original function but actively stiffen the tissue around them, making the environment more attractive to fibrosis-promoting cells.

And while this study focused on epithelial cells – those at the interface between lung tissue and air – the researchers plan to expand their work to other key players in fibrosis: macrophages, fibroblasts and neutrophils.

“This is just the first step,” says Loebel. “Now that we’ve built this tool, we can use it to look at cell-specific contributions to fibrosis, not just in the lungs, but potentially in other organs like the liver or skin, where fibrosis also causes major health problems.”

A blueprint for future therapies

Ultimately, the hope is that by understanding how stiffness affects cells in the earliest phases of fibrosis, scientists and doctors can better predict who’s at risk and when to intervene.

“We’re not trying to recreate fibrosis in the lab,” Loebel says. “We’re identifying its starting point. If we can understand the first responders, we can work toward treatments that prevent the entire cascade from happening.”

When starved of oxygen during a heart attack or stroke, cells unleash a flurry of emergency measures to protect themselves and the body. For decades, scientists have observed that the body’s production of a “three-tailed” fat molecule consistently surges during this trauma but have puzzled over why. Now, Cornell researchers have uncovered its surprising role in cellular survival: protecting against damage when oxygen runs out.

The research shows that the fat molecule, N-acylphosphatidylethanolamine (NAPE), helps cells survive ischemia – oxygen loss from reduced blood flow – by driving lactic acid out of cells. This toxic byproduct builds up during emergency metabolism, and NAPE’s surge appears to be part of the body’s protective response. Though still in an early stage, the findings suggest that boosting or mimicking NAPE could one day help limit tissue damage in heart attack and stroke.

The study, published Sept. 5 in the Journal of the American Chemical Society, was led by graduate student Din-Chi Chiu and Jeremy Baskin, associate professor and Nancy and Peter Meinig Family Investigator in the Life Sciences in the Department of Chemistry and Chemical Biology in the College of Arts and Sciences, and the Weill Institute for Cell and Molecular Biology.

“During heart attack or stroke, when there is an interruption in blood flow, the cells in the affected tissue, whether it is the heart or the brain, have to scramble to be able to continue to produce energy to survive,” Baskin said.

Under normal conditions, cells largely produce energy by a longer and much higher yielding process involving mitochondria.

“However, when energy needs are imminent and oxygen is limited, such as when blood flow is restricted, a metabolic switch occurs to favor glycolysis, which is a quick and dirty way of generating energy,” he said. “But to keep glycolysis going unabated, lactate, or lactic acid, is built up, and because it can be toxic at high levels, cells need to export it to prevent it from building up inside cells to undesirable levels.”

Because NAPE repels water and is short-lived in cells, studying it directly has been nearly impossible. The research team overcame this by designing and synthesizing a chemical “look-alike” probe that tagged NAPE’s protein partners under UV light, revealing its interactions.

The researchers observed NAPE latching onto proteins that regulate lactate transport. In particular, it bound to two cell-surface proteins, CD147 and CD44, which control transport proteins that act like gates controlling how lactic acid moves in and out of cells. The team’s experiments showed that when NAPE levels rise, lactate transport ramps up, and blocking those transporters erased the effect.

“The work reframes NAPE as a signaling molecule,” Baskin said. “Our finding that NAPE can stimulate lactate export supports a model in which the role of NAPE in pathological events such as heart attack or stroke is part of a protective response.”

For now, the team is exploring whether different versions of NAPE, with different tail compositions, might fine-tune lactate regulation in unique ways. They are also interested in whether NAPE plays roles in other tissues beyond the heart and brain.

“Future studies in heart and brain tissue will test this hypothesis more directly,” Baskin said. “If confirmed, the work could support the creation of therapies that boost NAPE levels as a way to limit tissue damage in cardiovascular emergencies.”

Other contributors to the research were graduate student Yuan-Ting Cho, a member of Baskin’s lab at the Weill Institute, and Hening Lin, professor of medicine and chemistry at the University of Chicago.

This research was supported by the National Institutes of Health and by the Howard Hughes Medical Institute.

Stephen D’Angelo is the communications manager for biological systems at Cornell Research and Innovation.

A COVID-19 misinformation-busting messaging intervention that presented a myth followed by a fact among people who had completed the initial vaccine series strengthened their resolve to follow up with a booster dose, suggests a University of Pennsylvania study published last week in Vaccine.

For the randomized controlled experiment, the researchers randomly assigned 892 racially diverse US adults with vaccine safety concerns to receive no message (control arm) or one of three message types: (1) a myth followed by fact, (2) a fact followed by a myth and the fact again, (3) or a fact only. The team then surveyed participants about their intent to receive the initial COVID-19 vaccine series or a booster in the next 3 and 12 months.

Concerns about turning people off to vaccination

Participants’ ages ranged from 18 to 79 years (average, 36 years), about half were men, a fifth were Hispanic, 40% were non-White, a quarter were Republicans, and a third were Democrats.

The myths were: “The COVID-19 vaccine causes infertility,” “It’s safer to get COVID-19 than to get the COVID-19 vaccine,” and “The effectiveness and safety of the COVID-19 vaccine cannot be trusted.”

“Attempts to correct misinformation often use one of three common message structures,” the researchers wrote. “The effectiveness of these message structures is unclear, and concerns have been raised that some can ‘backfire’ by weakening vaccination intentions.”

For example, some experts believe that the traditional myth-fact approach used by many public health organizations throughout the COVID-19 pandemic may inadvertently reinforce the myth by repeating it. 

“People may have difficulty recalling whether the information was categorized as the myth or fact because the context is forgotten,” the study authors wrote. “In addition, people show an increased liking for stimuli when they are exposed to them more often.”

No impact on booster intent in unvaccinated 

Of 531 participants who had received zero or one COVID-19 vaccine doses, 65% said they had no intention of receiving a dose in the next 12 months, 28% reported weak intentions, and 7% reported strong intentions. Of 361 recipients of two or more doses, 16% said they had no intention of getting a booster within the first 12 months it was available to them, 37% reported weak intentions, and 48% indicated strong intentions.

Exposure to the myth-followed-by-fact message was associated with stronger booster intentions among participants who had received an initial COVID-19 vaccine dose than those among controls. Of those who hadn’t received the initial vaccine series, the strength of intent to begin vaccination was the same across all study groups. 

Receiving one COVID-19 vaccine dose (compared with zero), higher financial stress, and a Democratic political affiliation were significantly related to stronger intentions to receive the vaccine in the next 12 months. 

Among participants who had completed the initial two-shot series, the intention to receive a COVID-19 booster in the first 12 months it was available to them was stronger among those who viewed the myth followed by the fact than in those who received no message. The fact-myth-fact and fact-only messages didn’t significantly strengthen or weaken booster intentions. 

Probably not reinforcing the myth

“In this study, only one of the three debunking message structures was effective, but none had counterproductive consequences, despite fears that they ‘backfire,’” the researchers wrote. “Therefore, the results did not suggest the messages repeating the myth are reinforcing the myth.” 

Children with sickle cell disease (SCD) are more likely to experience dental complications, yet fewer than half of those enrolled in Michigan Medicaid received dental care in 2022, according to a new study published in JAMA Network Open.^1,2

The study, led by researchers at Michigan Medicine and the RAND Corporation, examined Medicaid dental claims for 1,096 children with SCD and compared them with claims from more than 1.18 million Medicaid-enrolled children in Michigan. Despite increased risk for oral health problems, children with SCD had dental care utilization rates comparable to the general Medicaid pediatric population.

“Sickle cell disease is known to increase the risk of dental complications in children, which underscores the importance of preventive dental care for this population,” said senior author Sarah Reeves, PhD, MPH, an associate professor of pediatrics and epidemiology at the University of Michigan Medical School and the Susan B. Meister Child Health Evaluation and Research (CHEAR) Center.

Study design and findings

Using validated case definitions from the Michigan Sickle Cell Data Collection program, investigators analyzed dental claims for preventive services, treatment, and overall utilization. The analysis followed STROBE reporting guidelines and used Centers for Medicare & Medicaid Services data for comparison.

Results showed that 42% of children with SCD received any dental services in 2022, compared with 44% of the general Medicaid population. Preventive dental care was received by 38% of children with SCD compared with 40% of peers without SCD. Treatment services were accessed by 15% of children with SCD versus 18% of other Medicaid-enrolled children.

When analyzed by age group, some disparities emerged. For example, children aged 6 to 14 years with SCD were significantly less likely to receive any dental services (50% vs 54%) and preventive dental services (46% vs 51%) compared with their peers. In contrast, children aged 1 to 5 years with SCD had slightly higher utilization rates, although these differences were not statistically significant.

Clinical significance

The authors emphasized the importance of preventive dental care for children with SCD due to the disease’s reciprocal relationship with oral health. Dental infections can trigger or worsen SCD complications by causing inflammation and red blood cell sickling.

“Oral infections are especially dangerous for people with sickle cell disease because they can trigger or worsen symptoms and serious complications,” Reeves said. “Preventative dental care helps reduce the risk of pain crises and hospitalizations.”

Despite these risks, access barriers persist. Medicaid covers pediatric dental services, and guidelines recommend annual visits for children. However, both children with and without SCD in the study showed low utilization rates.

Barriers and recommendations

The study noted several barriers limiting dental care access for children with SCD, including limited participation of dentists in Medicaid programs and a lack of clear clinical guidance for treating these patients.

“Our findings show that we need to take steps to make sure kids with this condition get the dental care they need—by helping dentists feel more prepared to treat them and making sure doctors know how important dental health is for these children,” Reeves said.

Targeted interventions may include improved training for dental providers, stronger coordination between medical and dental professionals, and expanded research on structural barriers.

“Given increased risk of oral health problems among patients with sickle cell disease we need focused efforts to expand access to dental services for them,” Reeves said. “There are many reasons why dental care rates are low in this group. Future research should look at what those barriers are and how we can overcome them to improve care for this vulnerable population.”

The study highlights the need for improved strategies to ensure preventive dental care reaches children with SCD, underscoring its role in preventing serious health complications.

References

1. Michigan Medicine – University of Michigan. Children with sickle cell disease face higher risk of dental issues, yet many don’t receive needed care. Eurekalert. September 3, 2025. Accessed September 5, 2025. https://www.eurekalert.org/news-releases/1096502
2. Kranz A, Peng HK, King AA, Clark SJ, Plegue MA, Reeves SL. Sickle Cell Disease and Dental Care Access Among Medicaid-Enrolled Youths. JAMA Network Open. 2025;8(9):e2529849-e2529849. doi:https://doi.org/10.1001/jamanetworkopen.2025.29849

Many infectious diseases are sensitive to certain climates and thrive in others. Consider malaria, which is rife in warm, humid, wet climates, and practically nonexistent in areas with cold temperatures or high altitudes. Given the fact that many of these climate variables can be observed from space, this allows users to predict where certain disease outbreaks may occur.

On October 7 and 9, 2025, NASA’s Applied Remote Sensing Training Program (ARSET) is offering a two-part, live, online training on the use of NASA satellite data for tracking climate-sensitive vector-borne disease outbreaks. Those who attend will learn about general approaches when applying satellite remote sensing data to studying or forecasting climate-sensitive infectious diseases. These will be illustrated with a case study example showing how remote sensing has been used to forecast malaria outbreaks. 

This training will also present some common, freely available NASA remote sensing datasets used in these applications, as well as where and how to access them, and how to decide which datasets are fit for this purpose.

This training is open to the public and is recommended for biostatisticians, medical students, vector ecologists, biologists studying disease vector organisms, public health officials, and non-governmental organizations (NGOs) tasked with monitoring and preparing for infectious disease outbreaks.